M2 PHARMA-September 4, 2019-Sandoz announces global commercialisation deal for multiple sclerosis biosimilar
M2 EQUITYBITES-September 4, 2019-Sandoz announces global commercialisation deal for multiple sclerosis biosimilar
Global Banking News-September 3, 2019-Polpharma Biologics signs global commercialisation agreement for biosimilar
Natalizumab for MS
Fact.MR has announced the addition of the "Pegfilgrastim Biosimilar
Market Forecast, Trend Analysis & Competition Tracking - Global Review 2018 to 2028"report to their offering.
Coherus BioSciences is a leading biosimilar
company that develops and commercializes high-quality therapeutics for major regulated markets.
As prescription drug costs continue to increase, biosimilar
medicines represent hope for patients seeking access to more affordable treatment.
M2 PRESSWIRE-July 29, 2019-: Biosimilar
Market Trends Report 2019: EU Guidelines, US Guidelines, Interchangeability, Patent and Patent Dance Issues
Amgen (AMGN) and Allergan (AGN) announced that Mvasi, a biosimilar
to Avastin, and Kanjinti, a biosimilar
to Herceptin, are now available in the United States.
(Alliance News) - US biopharmaceutical firm Amgen Inc said Thursday two of its biosimilar
cancer treatments are now available in the US.
* Biogen's three biosimilar
treatments--BENEPALI[TM] (etanercept), FLIXABI[TM] (infliximab) and IMRALDI[TM] (adalimumab)--are estimated to save the European healthcare system 1.8 billion euros in 2019
The agreement covers multiple biosimilar
candidates from Samsung Bioepis, including third-wave biosimilar
candidates SB11 and SB12, which reference Lucentis (ranibizumab) and Soliris (eculizumab), respectively, as well as SB3, a biosimilar
candidate referencing Herceptin 3 (trastuzumab).